Efficacy of clarithromycin against Streptococcus pneumoniae expressing mef(A)-mediated resistance

International Journal of Antimicrobial Agents

Volumn 23, Issue 5, 2004, Pages 498-501

  Maglio, Dana ^a   Capitano, Blair ^a   Banevicius, Mary Anne ^a   Tessier, Pamela R ^a   Nightingale, Charles H ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Clarithromycin; Low level macrolide resistance; Murine pneumonia model; S. pneumoniae

Indexed keywords

CLARITHROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; INHIBITION KINETICS; LOBAR PNEUMONIA; MEFA GENE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CLARITHROMYCIN; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; IMMUNOCOMPROMISED HOST; LUNG; MEMBRANE PROTEINS; METHYLTRANSFERASES; MICE; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 2342477802     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.09.028     Document Type: Article

References (11)

1. Bishai W. The in vivo-in vitro paradox in pneumococcal respiratory tract infections. J. Antimicrob. Chemother. 49:2002;433-436
2. Doern G.V., Heilmann K.P., Huynh H.K., Rhomberg P.R., Coffam S.L., Brueggemann A.B. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. 45:2001;1721-1729
3. Siegel R.E. The significance of serum vs. tissue levels of antibiotics in the treatment of penicillin-resistant Streptococcus pneumoniae and community-acquired pneumonia. Chest. 116:1999;535-538
4. Andes D., Craig W.A. In vivo activities of amoxicillin and amoxicillin-clavulanate against S. pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:1998;2375-2379
5. Joly-Guillou M.L., Wolff M., Pocidalo J.J., Walker F., Carbon C. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob. Agents Chemother. 41:1997;345-351
6. Tessier P.R., Kim M.K., Zhou W., et al. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob. Agents Chemother. 46:2002;1425-1434
7. Hoffman H.L., Klepser M.E., Ernst E.J., Petzold C.R., Sa'adah L.M., Doern G.V. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. Antimicrob. Agents Chemother. 47:2003;739-746
8. Rodvold K.A., Gotfried M.H., Danziger L.H., Servi R.J. Intrapulmonary steady-state concentrations of clarithromycin and azithromcyin in healthy adult volunteers. Antimicrob. Agents Chemother. 41:1997;1399-1402
9. Noreddin A.M., Roberts D., Nichol K., Wierzbowski A., Hoban D.J., Zhanel G.G. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob. Agents Chemother. 46:2002;4029-4034
10. Cuffini A.M., Tullio V., Mandras N., et al. Clarithromycin mediated the expression of polymorphonuclear granulocyte response against Streptococcus pneumoniae strains with different patterns of susceptibility and resistance to penicillin and clarithromycin. Int. J. Tissue React. 24:2002;37-44
11. Culic O., Erakovic V., Parnham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur. J. Pharmacol. 429:2001;209-229